0812 GMT - Fresenius Medical Care's revenue estimates have been lowered by Jefferies due to constrained U.S. volume growth compared to prepandemic levels and a diverging growth outlook from U.S. rival DaVita, its analysts write. The German dialysis provider guides for 0.5% U.S. volume growth in 2025 and expects volumes to recover by 2% in 2026. On the contrary, DaVita guides for flat volume growth at the midpoint of its guidance in 2025 and refrained from long-term comments, hinting at a potentially slower growth across the market. Consequently, Jefferies lowers its 2025-29 revenue estimate but increases its adjusted EBIT target on the company's higher margins and raised savings ambitions. Jefferies analysts look for more updates on its strategy and future growth prospects at its June CMD, they add. Shares fall 0.9% to 45.07 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 21, 2025 04:19 ET (08:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。